Sugi Predict

Sugi Predict / Compounds / SCHEMBL5470804

SCHEMBL5470804

SCHEMBL5470804

CCOC(=O)c1cc2n[nH]c(=O)n2c2cc(Cl)c(OC)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 7/20 0.41
▸ MAPT P10636 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ DPP4 P27487 2/20 0.39
▸ BAZ2B Q9UIF8 1/20 0.38
▸ BAZ2A Q9UIF9 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ PDE5A O76074 2/20 0.37
▸ PDE6D O43924 1/20 0.37
▸ PDE6A P16499 1/20 0.37
▸ PDE6G P18545 1/20 0.37
▸ PDE6B P35913 1/20 0.37
▸ PDE6C P51160 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473473 0.86 CHEK1 (0.45) CHEK1
SCHEMBL5483386 0.82 CHEK1 (0.41) CHEK1MAPTGAATHRBKMT2A
SCHEMBL5465758 0.81 CHEK1 (0.57) CHEK1
SCHEMBL5470116 0.81 CHEK1 (0.50) CHEK1MAPTGAAL3MBTL1MEN1
SCHEMBL5470789 0.79 CHEK1 (0.47) CHEK1GAAL3MBTL1MEN1KMT2A
SCHEMBL5465690 0.78 CHEK1 (0.61) CHEK1MAPTGAANPSR1L3MBTL1
SCHEMBL5476504 0.78 CHEK1 (0.54) CHEK1GAA
SCHEMBL5480737 0.78 CHEK1 (0.58) CHEK1ALDH1A1
SCHEMBL5478071 0.78 LMNA (0.52) CHEK1MAPTMEN1KMT2AALDH1A1
SCHEMBL5473148 0.71 CHEK1 (0.51) CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 — — US claimed
JP-2006520397-A — — 2006-09-07 — — JP claimed
EP-1613625-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF AstraZeneca AB (SE) 2006-01-11 — — EP claimed
WO-2004081008-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 — — WO claimed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 — — US disclosed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 — — US disclosed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 — — US disclosed
EP-1613625-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF AstraZeneca AB (SE) 2006-01-11 — — EP disclosed
WO-2004081008-A1 NOVEL FUSED TRIAZOLONES AND THE USES THEREOF ASTRAZENECA AB (SE) 2004-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149560-A1 Novel fused triazolones and the uses thereof TP53, BRCA1, KLK3 CHEK1 13/4885MAPT 2300/4885GAA 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.